Status:
RECRUITING
Royal Jelly as a Strategy to Modulate Inflammation and Oxidative Stress in Patients With Systemic Arterial Hypertension
Lead Sponsor:
Universidade Federal Fluminense
Conditions:
Hypertension
Cardiovascular Diseases (CVD)
Eligibility:
All Genders
18-75 years
Phase:
NA
Brief Summary
The study aims to evaluate the effect of the royal jelly on inflammation and oxidative stress in participants with systemic arterial hypertension. A longitudinal double-blind randomized clinical trial...
Detailed Description
Royal jelly (RG) is considered a superfood that has been used in traditional medicine and dietary supplementation due to its antioxidant, anti-inflammatory, immunomodulatory, and regenerative properti...
Eligibility Criteria
Inclusion
- patients using one to three antihypertensive medications, undergoing regular follow-up at the HUAP Medical Clinic for more than 6 months and without the need for changes in medication doses in the last 3 months.
Exclusion
- Patients with autoimmune and infectious diseases, diabetes, chronic kidney disease, liver disease, cancer and AIDS will be excluded; pregnant women; those using catabolic drugs or antibiotics; use of antioxidant vitamin supplements, prebiotics, probiotics, symbiotics, habitual intake of royal jelly, and who are allergic to cornstarch or report having an allergy to bee stings will also be excluded. Patients with acute myocardial infarction (AMI) and/or stroke (CVA) in the last 6 months will also be excluded; with HAS stages 2 or 3.
Key Trial Info
Start Date :
September 18 2024
Trial Type :
INTERVENTIONAL
Allocation :
ESTIMATED
End Date :
December 20 2025
Estimated Enrollment :
34 Patients enrolled
Trial Details
Trial ID
NCT06917131
Start Date
September 18 2024
End Date
December 20 2025
Last Update
April 8 2025
Active Locations (1)
Enter a location and click search to find clinical trials sorted by distance.
1
Denise Mafra
Rio de Janeiro, Brazil, 22260050